Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

A Randomized, Double-blind, Placebo and Calibrator Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Doses of VAK694 in Subjects With Seasonal Rhinitis During Natural Exposure to Allergen

This study will assess the safety and tolerability of multiple doses of VAK694 as well as change in symptoms and biomarkers in patients with seasonal allergic rhinitis

Inclusion Criteria:

• Male and female subjects between ages of 18 to 60 in good health
• History of atopy for at least 2 years and positive skin prick test to ragweed allergen

Exclusion criteria:

• History of asthma treated with corticosteroids
• Smokers with a smoking history of > 10 pack/years or smoking in the past year
• History of chronic obstructive pulmonary disease

Other protocol-defined inclusion/exclusion criteria may apply